Video

Transitions of Care and Patient Follow-Up

Michael A. Evans, BS, RPh, describes why patient follow-up is necessary during transitions of care scenarios following the initiation of treatment with an anticoagulant. Warfarin therapy requires close, regular monitoring by a patient’s healthcare team; thus, the management of patients taking warfarin can be a challenge, especially during transitions of care, notes Mr Evans. In contrast, he adds, the management of patients taking direct-acting oral anticoagulants is comparatively easier, as these agents do not require routine monitoring.

Regardless of which treatment option is prescribed for a patient, patient follow-up is important during transitions of care scenarios because it can help prevent drug-related adverse events and thromboembolic complications, says Mr Evans. Patients and their caregivers need to be educated about the purpose of their treatment, the potential for side effects and drug-drug interactions, and the importance of taking their treatment as prescribed. The nature and frequency of follow-up care should be individualized following an assessment by a clinician, he suggests.

Institutions should establish protocols for appropriate follow-up care, which includes follow-up phone calls. The individual that makes the follow-up phone calls with the patient following a transition of care need not be the physician. Rather, any member of a patient’s multidisciplinary care team (eg, a nurse, pharmacist, assistant) can make follow-up phone calls.


Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Leigh Maria Ramos-Platt, MD
Molly Dean, MSW, Siftwell
Tiffany Meng, PharmD, oncology pharmacist with UCSF Health
Tiffany Meng, PharmD, oncology pharmacist, UCSF Health
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo